Patients whose gliomas, even high-grade gliomas, have methylation of the promoter region of the gene for MGMT (which thereby suppresses expression of this DNA repair enzyme) have better response to radiation and alkylator chemotherapy and have longer survival. The gene discussed is MGMT; the disease is central nervous system cancer.